A discrepancy has been reported regarding the JAK2 V617F mutation in patients with essential thrombocythemia and polycythemia vera, and also regarding the type A mutation of NPM1 in acute myeloid leukemia (AML) [20,21,22]. Here, JAK2 is linked to essential thrombocythemia.